---
title: "Design Therapeutics, Inc. (DSGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DSGN.US.md"
symbol: "DSGN.US"
name: "Design Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T10:42:39.340Z"
locales:
  - [en](https://longbridge.com/en/quote/DSGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DSGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DSGN.US.md)
---

# Design Therapeutics, Inc. (DSGN.US)

## Company Overview

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.designtx.com](https://www.designtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.59 | 450 | - | - | - |
| PB | 3.06 | 254 | 2.98 | 2.16 | 1.01 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Overweight | 2 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.70 |
| Highest Target | 20.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DSGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DSGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DSGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DSGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**